{"id":420245,"date":"2021-01-25T08:48:13","date_gmt":"2021-01-25T13:48:13","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=420245"},"modified":"2021-01-25T08:48:13","modified_gmt":"2021-01-25T13:48:13","slug":"lyfebulb-and-csl-behring-launch-transplantlyfe-a-first-of-its-kind-community-engagement-platform-for-transplant-patients","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lyfebulb-and-csl-behring-launch-transplantlyfe-a-first-of-its-kind-community-engagement-platform-for-transplant-patients\/","title":{"rendered":"Lyfebulb and CSL Behring Launch TransplantLyfe, a First-of-its-Kind Community Engagement Platform for Transplant Patients"},"content":{"rendered":"<div class=\"xn-newslines\">\n<h2 class=\"xn-hedline\">&#8211; TransplantLyfe is an online community for those living with an organ transplant, their support partners and donors to share experiences, find one-on-one mentorships and help individuals feel safe as they embrace struggles unique to transplantation, regardless of their physical location.<\/h2>\n<h2 class=\"xn-hedline\">&#8211; TransplantLyfe addresses a major unmet need for those living with organ transplantation: most notably, the support and communication gap between individuals with similar experiences in the transplant journey.<\/h2>\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">NEW YORK<\/span>, <span class=\"xn-chron\">Jan. 25, 2021<\/span> \/PRNewswire\/ &#8212;\u00a0Global biotherapeutics leader CSL Behring, and patient empowerment platform, Lyfebulb, announced today the launch of a first-of-its-kind online community support platform, TransplantLyfe, which is dedicated to providing transplant patients, their support partners and donors with the support they need in the transplant journey. Given the relatively low number of individuals undergoing an organ transplant each year, finding others with similar experiences in a local community can be difficult. By providing an active online community, solely focused on transplantation, TransplantLyfe enables connections with others who can relate and provide insights and advice.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/783693\/Lyfebulb.html\" target=\"_blank\" rel=\"nofollow noopener noreferrer\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/783693\/Lyfebulb.jpg\" title=\"(PRNewsfoto\/Lyfebulb)\" alt=\"(PRNewsfoto\/Lyfebulb)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>While transplant patients are closely connected to their healthcare team post-surgery to ensure a safe physical recovery, they may feel emotionally disconnected and experience sensations of guilt and loneliness as they begin to process the mental impact of receiving a transplant.<sup>1<\/sup><\/p>\n<p>Following an organ transplant, patients may have concerns for their future, including fear of organ failure; high anxiety; difficulty managing the burdens of their treatment regimen; social emotional impact; and limitations of their physical activity.<sup>2<\/sup><\/p>\n<p>TransplantLyfe allows users to share their questions and experiences, and to find companionship and support without being limited to their local community. The ability to identify with others&#8217; stories, remain anonymous or connect one-on-one with peers may help improve a patient&#8217;s sense of security and inspire them to thrive with their transplant \u2013 not just survive.<\/p>\n<p>&#8220;CSL Behring is proud to partner in the development and launch of TransplantLyfe \u2013 a critical tool that can directly help provide support to patients and their care team,&#8221; said <span class=\"xn-person\">Kevin Kovaleski<\/span>, Vice President, Global Commercial Development, Transplant, CSL Behring. &#8220;The opportunity to be a part of changing the way that transplantation is managed and cared for is one that closely aligns with delivering on our promise to address unmet needs in the transplant community.&#8221;<\/p>\n<p>TransplantLyfe was developed as part of an open and honest dialogue with the transplant community to identify and help fulfil the needs of transplant patients, their care partners and donors throughout their journey. <\/p>\n<p>&#8220;As a transplant recipient myself, the creation of TransplantLyfe is extremely personal and is at the very core of the reason Lyfebulb was founded: patients need patients,&#8221; said <span class=\"xn-person\">Karin Hehenberger<\/span><b>, <\/b>MD, PhD, Founder &amp; CEO, Lyfebulb. &#8220;The ability to have partnered with CSL Behring, a company dedicated to making strides to improve the continuum of care in transplantation, was pivotal in developing this platform that will serve the needs of thousands of transplant patients across the country.&#8221;<\/p>\n<p>In addition to managing the physical side effects of anti-rejection medications, transplant patients often carry an emotional burden from the surgery, which can develop into mood disorders, such as anxiety and depression.<sup>3,4<\/sup> While there may be a feeling of euphoria immediately following transplant surgery, patients can face a complex range of emotions \u2013 including anguish, fear, distress and happiness \u2013 as they navigate life post-transplant.<sup>4<\/sup><\/p>\n<p>TransplantLyfe users will be able to make connections to share stories with others, participate in Q&amp;A forums, access information through vetted resources and create journals to track biometrics and other health measurements over time.\u00a0 <\/p>\n<p>For more information on TransplantLyfe or to register, please visit <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3045006-1&amp;h=1779025067&amp;u=https%3A%2F%2Fwww.transplantlyfe.com%2F&amp;a=https%3A%2F%2Fwww.transplantlyfe.com%2F\" rel=\"nofollow noopener noreferrer\">https:\/\/www.transplantlyfe.com\/<\/a>.<\/p>\n<p>\n        <b>About Lyfebulb<\/b>\n      <\/p>\n<p>Lyfebulb is a chronic disease-focused, patient empowerment platform that connects patients and industry to support user-driven innovation. Grounded with its strong foundation in diabetes, the company has expanded disease states covered into cancer, inflammatory bowel disease, multiple sclerosis, mental health, substance use disorder, migraine, transplantation, psoriasis, chronic cough, and chronic kidney disease. <\/p>\n<p>See\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3045006-1&amp;h=1310842023&amp;u=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DzzOY0X0U5Jh2b59yOOa8Tha3ZJq0cCFXyuzTtbdtauarEe2P7dX2ic1eRgR948oe5sVLUmJtAqTlVyQzZkkb9g%3D%3D&amp;a=Lyfebulb.com\" rel=\"nofollow noopener noreferrer\">Lyfebulb.com<\/a>,\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3045006-1&amp;h=3251116899&amp;u=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DHST9SCbcXFqRt-dp9NDqnwKpiUmD9SYwyVRrIx-XbayXT1Py0a-kNHB9cFXrLYV8RRNjAu3Ln7OKF0m4snrtGbsQ3V8kvehuPHtC9-rTj3LW-V45hO-QXBa3z7tynhHD&amp;a=Facebook\" rel=\"nofollow noopener noreferrer\">Facebook<\/a>,\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3045006-1&amp;h=89719875&amp;u=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3D-SKnStQWunDcNOODnd6gGNMZ5FtvokMw6HZ7ePSmLUajeAOAh5NB9cOG1KchVNjFlPtAw1pcC8oFowDiF3-5Ww%3D%3D&amp;a=Twitter\" rel=\"nofollow noopener noreferrer\">Twitter<\/a>,\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3045006-1&amp;h=3398121196&amp;u=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DC0EwIZEDDGaLg0co_grXQAKItZ2yeRtePNKizmpVCDJ13kwsGjj1I-joOWSn-ShoR69q0GxH7LLC_dSp-XQY3yQ7b3CpFuoiWp4ABvT4K8c%3D&amp;a=Instagram\" rel=\"nofollow noopener noreferrer\">Instagram<\/a>,\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3045006-1&amp;h=1719279494&amp;u=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3DP51W7Dl8V8IvuxvdlBDLl4lNGlx4_TzrNNAg0dSGBIex_pqyyVvGe6ahqQfBJzCcHijiOiHrsQZWghocLEnOkFJpu0A4yQw1hzd0hNsIy8VFkUqO8vGm3djU39j5CX2lrLqpEmXe_Zt215UO7QRC2A%3D%3D&amp;a=Karin+Hehenberger+LinkedIn\" rel=\"nofollow noopener noreferrer\">Karin Hehenberger LinkedIn<\/a>, and\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3045006-1&amp;h=3570628583&amp;u=https%3A%2F%2Fwww.globenewswire.com%2FTracker%3Fdata%3D7UiH1ImKAVGV8lKO3l9VqbprmTZUDQdGIvdktpKiTx0sxp65Xgpc5PhI2IP53qbPO1PvLTi0TFGVaLsC1RXd1x--uX5R87C0OPRuMPlpAT4%3D&amp;a=Lyfebulb+LinkedIn\" rel=\"nofollow noopener noreferrer\">Lyfebulb LinkedIn<\/a>.<\/p>\n<p>\n        <b>About CSL Behring<\/b>\n      <\/p>\n<p>\n        <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3045006-1&amp;h=775350869&amp;u=http%3A%2F%2Fwww.cslbehring.com%2F&amp;a=CSL+Behring\" rel=\"nofollow noopener noreferrer\">CSL Behring<\/a>\u00a0is a global biotherapeutics leader driven by its promise to save lives. Focused on serving patients&#8217; needs by using the latest technologies, CSL Behring develops and delivers innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, respiratory disease, and neurological disorders. The company&#8217;s products are also used in cardiac surgery, burn treatment and to prevent hemolytic disease of the newborn.<\/p>\n<p>CSL Behring operates one of the world&#8217;s largest plasma collection networks, CSL Plasma. The parent company,\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3045006-1&amp;h=3910621156&amp;u=http%3A%2F%2Fwww.csl.com%2F&amp;a=CSL+Limited\" rel=\"nofollow noopener noreferrer\">CSL Limited<\/a>\u00a0(ASX:CSL;USOTC:CSLLY), headquartered in <span class=\"xn-location\">Melbourne, Australia<\/span>, employs more than 27,000 people, and delivers its life-saving therapies to people in more than 100 countries. For inspiring stories about the promise of biotechnology, visit Vita\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3045006-1&amp;h=3409542370&amp;u=http%3A%2F%2Fwww.cslbehring.com%2Fvita&amp;a=CSLBehring.com%2Fvita\" rel=\"nofollow noopener noreferrer\">CSLBehring.com\/vita<\/a>\u00a0and follow CSL Behring on\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3045006-1&amp;h=1162077953&amp;u=https%3A%2F%2Ftwitter.com%2FCSLBehring&amp;a=Twitter.com%2FCSLBehring\" rel=\"nofollow noopener noreferrer\">Twitter.com\/CSLBehring<\/a>.<\/p>\n<p>\n        <b>Lyfebulb Contact:<\/b><br \/>\n        <br \/>\n        <span class=\"xn-person\">Karin Hehenberger<\/span>, MD, PhD<br \/>CEO &amp; Founder, Lyfebulb<br \/>Phone: + 1 917-575-0210<br \/>Email: <a target=\"_blank\" href=\"mailto:karin@lyfebulb.com\" rel=\"nofollow noopener noreferrer\">karin@lyfebulb.com<\/a><\/p>\n<p>\n        <b>CSL Behring Contact:<\/b><br \/>\n        <br \/>\n        <span class=\"xn-person\">Jennifer Purdue<\/span><br \/>\n        <br \/>External Communications Manager<br \/>Phone: +1 610-306-9355<br \/>Email: <a target=\"_blank\" href=\"mailto:jennifer.purdue@cslbehring.com\" rel=\"nofollow noopener noreferrer\">jennifer.purdue@cslbehring.com<\/a><\/p>\n<p>\n        <b>References<\/b><br \/>\n        <br \/>1. Schulz K, Kroencke S. Psychosocial challenges before and after organ transplantation.\u00a0<i>Transplant Research and Risk Management<\/i>. 2015;7:45-58 <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3045006-1&amp;h=3490063313&amp;u=https%3A%2F%2Fdoi.org%2F10.2147%2FTRRM.S53107&amp;a=https%3A%2F%2Fdoi.org%2F10.2147%2FTRRM.S53107\" rel=\"nofollow noopener noreferrer\">https:\/\/doi.org\/10.2147\/TRRM.S53107<\/a>.<br \/>2. Center for Drug Evaluation and Research (CDER); U.S. Food and Drug Administration (FDA). The Voice of the Patient: Patients Who Have Received An Organ Transplant. <span class=\"xn-chron\">April 2017<\/span>. <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3045006-1&amp;h=4040757044&amp;u=https%3A%2F%2Fwww.fda.gov%2Fmedia%2F105219%2Fdownload&amp;a=https%3A%2F%2Fwww.fda.gov%2Fmedia%2F105219%2Fdownload\" rel=\"nofollow noopener noreferrer\">https:\/\/www.fda.gov\/media\/105219\/download<\/a>. <br \/>3. National Kidney Foundation. <i>Immunosuppresants<\/i>. <span class=\"xn-chron\">June 2020<\/span>. <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3045006-1&amp;h=1714797228&amp;u=https%3A%2F%2Fwww.kidney.org%2Fatoz%2Fcontent%2Fimmuno&amp;a=https%3A%2F%2Fwww.kidney.org%2Fatoz%2Fcontent%2Fimmuno\" rel=\"nofollow noopener noreferrer\">https:\/\/www.kidney.org\/atoz\/content\/immuno<\/a>. <br \/>4. De Pasquale, C., Veroux, M., Indelicato, L., Sinagra, N., Giaquinta, A., Fornaro, M., Veroux, P., &amp; Pistorio, M. L. (2014). Psychopathological aspects of kidney transplantation: Efficacy of a multidisciplinary team. World journal of transplantation, 4(4), 267\u2013275. <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3045006-1&amp;h=3725544957&amp;u=https%3A%2F%2Fdoi.org%2F10.5500%2Fwjt.v4.i4.267&amp;a=https%3A%2F%2Fdoi.org%2F10.5500%2Fwjt.v4.i4.267\" rel=\"nofollow noopener noreferrer\">https:\/\/doi.org\/10.5500\/wjt.v4.i4.267<\/a>.\u00a0<\/p>\n<p>\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/1425056\/CSL_BEHRING_Logo.html\" target=\"_blank\" rel=\"nofollow noopener noreferrer\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/1425056\/CSL_BEHRING_Logo.jpg\" title=\"CSL Behring Logo\" alt=\"CSL Behring Logo\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY56667&amp;sd=2021-01-25\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/lyfebulb-and-csl-behring-launch-transplantlyfe-a-first-of-its-kind-community-engagement-platform-for-transplant-patients-301213644.html\">http:\/\/www.prnewswire.com\/news-releases\/lyfebulb-and-csl-behring-launch-transplantlyfe-a-first-of-its-kind-community-engagement-platform-for-transplant-patients-301213644.html<\/a><\/p>\n<p>SOURCE  Lyfebulb<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NY56667&amp;Transmission_Id=202101250845PR_NEWS_USPR_____NY56667&amp;DateId=20210125\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&#8211; TransplantLyfe is an online community for those living with an organ transplant, their support partners and donors to share experiences, find one-on-one mentorships and help individuals feel safe as they embrace struggles unique to transplantation, regardless of their physical location. &#8211; TransplantLyfe addresses a major unmet need for those living with organ transplantation: most notably, the support and communication gap between individuals with similar experiences in the transplant journey. PR Newswire NEW YORK, Jan. 25, 2021 \/PRNewswire\/ &#8212;\u00a0Global biotherapeutics leader CSL Behring, and patient empowerment platform, Lyfebulb, announced today the launch of a first-of-its-kind online community support platform, TransplantLyfe, which is dedicated to providing transplant patients, their support partners and donors with the support they need in the transplant &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lyfebulb-and-csl-behring-launch-transplantlyfe-a-first-of-its-kind-community-engagement-platform-for-transplant-patients\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Lyfebulb and CSL Behring Launch TransplantLyfe, a First-of-its-Kind Community Engagement Platform for Transplant Patients&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-420245","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Lyfebulb and CSL Behring Launch TransplantLyfe, a First-of-its-Kind Community Engagement Platform for Transplant Patients - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lyfebulb-and-csl-behring-launch-transplantlyfe-a-first-of-its-kind-community-engagement-platform-for-transplant-patients\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lyfebulb and CSL Behring Launch TransplantLyfe, a First-of-its-Kind Community Engagement Platform for Transplant Patients - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"&#8211; TransplantLyfe is an online community for those living with an organ transplant, their support partners and donors to share experiences, find one-on-one mentorships and help individuals feel safe as they embrace struggles unique to transplantation, regardless of their physical location. &#8211; TransplantLyfe addresses a major unmet need for those living with organ transplantation: most notably, the support and communication gap between individuals with similar experiences in the transplant journey. PR Newswire NEW YORK, Jan. 25, 2021 \/PRNewswire\/ &#8212;\u00a0Global biotherapeutics leader CSL Behring, and patient empowerment platform, Lyfebulb, announced today the launch of a first-of-its-kind online community support platform, TransplantLyfe, which is dedicated to providing transplant patients, their support partners and donors with the support they need in the transplant &hellip; Continue reading &quot;Lyfebulb and CSL Behring Launch TransplantLyfe, a First-of-its-Kind Community Engagement Platform for Transplant Patients&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/lyfebulb-and-csl-behring-launch-transplantlyfe-a-first-of-its-kind-community-engagement-platform-for-transplant-patients\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-25T13:48:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/783693\/Lyfebulb.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lyfebulb-and-csl-behring-launch-transplantlyfe-a-first-of-its-kind-community-engagement-platform-for-transplant-patients\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lyfebulb-and-csl-behring-launch-transplantlyfe-a-first-of-its-kind-community-engagement-platform-for-transplant-patients\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Lyfebulb and CSL Behring Launch TransplantLyfe, a First-of-its-Kind Community Engagement Platform for Transplant Patients\",\"datePublished\":\"2021-01-25T13:48:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lyfebulb-and-csl-behring-launch-transplantlyfe-a-first-of-its-kind-community-engagement-platform-for-transplant-patients\\\/\"},\"wordCount\":963,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lyfebulb-and-csl-behring-launch-transplantlyfe-a-first-of-its-kind-community-engagement-platform-for-transplant-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/783693\\\/Lyfebulb.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lyfebulb-and-csl-behring-launch-transplantlyfe-a-first-of-its-kind-community-engagement-platform-for-transplant-patients\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lyfebulb-and-csl-behring-launch-transplantlyfe-a-first-of-its-kind-community-engagement-platform-for-transplant-patients\\\/\",\"name\":\"Lyfebulb and CSL Behring Launch TransplantLyfe, a First-of-its-Kind Community Engagement Platform for Transplant Patients - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lyfebulb-and-csl-behring-launch-transplantlyfe-a-first-of-its-kind-community-engagement-platform-for-transplant-patients\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lyfebulb-and-csl-behring-launch-transplantlyfe-a-first-of-its-kind-community-engagement-platform-for-transplant-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/783693\\\/Lyfebulb.jpg\",\"datePublished\":\"2021-01-25T13:48:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lyfebulb-and-csl-behring-launch-transplantlyfe-a-first-of-its-kind-community-engagement-platform-for-transplant-patients\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lyfebulb-and-csl-behring-launch-transplantlyfe-a-first-of-its-kind-community-engagement-platform-for-transplant-patients\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lyfebulb-and-csl-behring-launch-transplantlyfe-a-first-of-its-kind-community-engagement-platform-for-transplant-patients\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/783693\\\/Lyfebulb.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/783693\\\/Lyfebulb.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lyfebulb-and-csl-behring-launch-transplantlyfe-a-first-of-its-kind-community-engagement-platform-for-transplant-patients\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lyfebulb and CSL Behring Launch TransplantLyfe, a First-of-its-Kind Community Engagement Platform for Transplant Patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lyfebulb and CSL Behring Launch TransplantLyfe, a First-of-its-Kind Community Engagement Platform for Transplant Patients - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/lyfebulb-and-csl-behring-launch-transplantlyfe-a-first-of-its-kind-community-engagement-platform-for-transplant-patients\/","og_locale":"en_US","og_type":"article","og_title":"Lyfebulb and CSL Behring Launch TransplantLyfe, a First-of-its-Kind Community Engagement Platform for Transplant Patients - Market Newsdesk","og_description":"&#8211; TransplantLyfe is an online community for those living with an organ transplant, their support partners and donors to share experiences, find one-on-one mentorships and help individuals feel safe as they embrace struggles unique to transplantation, regardless of their physical location. &#8211; TransplantLyfe addresses a major unmet need for those living with organ transplantation: most notably, the support and communication gap between individuals with similar experiences in the transplant journey. PR Newswire NEW YORK, Jan. 25, 2021 \/PRNewswire\/ &#8212;\u00a0Global biotherapeutics leader CSL Behring, and patient empowerment platform, Lyfebulb, announced today the launch of a first-of-its-kind online community support platform, TransplantLyfe, which is dedicated to providing transplant patients, their support partners and donors with the support they need in the transplant &hellip; Continue reading \"Lyfebulb and CSL Behring Launch TransplantLyfe, a First-of-its-Kind Community Engagement Platform for Transplant Patients\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/lyfebulb-and-csl-behring-launch-transplantlyfe-a-first-of-its-kind-community-engagement-platform-for-transplant-patients\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-25T13:48:13+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/783693\/Lyfebulb.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lyfebulb-and-csl-behring-launch-transplantlyfe-a-first-of-its-kind-community-engagement-platform-for-transplant-patients\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lyfebulb-and-csl-behring-launch-transplantlyfe-a-first-of-its-kind-community-engagement-platform-for-transplant-patients\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Lyfebulb and CSL Behring Launch TransplantLyfe, a First-of-its-Kind Community Engagement Platform for Transplant Patients","datePublished":"2021-01-25T13:48:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lyfebulb-and-csl-behring-launch-transplantlyfe-a-first-of-its-kind-community-engagement-platform-for-transplant-patients\/"},"wordCount":963,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lyfebulb-and-csl-behring-launch-transplantlyfe-a-first-of-its-kind-community-engagement-platform-for-transplant-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/783693\/Lyfebulb.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lyfebulb-and-csl-behring-launch-transplantlyfe-a-first-of-its-kind-community-engagement-platform-for-transplant-patients\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/lyfebulb-and-csl-behring-launch-transplantlyfe-a-first-of-its-kind-community-engagement-platform-for-transplant-patients\/","name":"Lyfebulb and CSL Behring Launch TransplantLyfe, a First-of-its-Kind Community Engagement Platform for Transplant Patients - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lyfebulb-and-csl-behring-launch-transplantlyfe-a-first-of-its-kind-community-engagement-platform-for-transplant-patients\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lyfebulb-and-csl-behring-launch-transplantlyfe-a-first-of-its-kind-community-engagement-platform-for-transplant-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/783693\/Lyfebulb.jpg","datePublished":"2021-01-25T13:48:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lyfebulb-and-csl-behring-launch-transplantlyfe-a-first-of-its-kind-community-engagement-platform-for-transplant-patients\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/lyfebulb-and-csl-behring-launch-transplantlyfe-a-first-of-its-kind-community-engagement-platform-for-transplant-patients\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lyfebulb-and-csl-behring-launch-transplantlyfe-a-first-of-its-kind-community-engagement-platform-for-transplant-patients\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/783693\/Lyfebulb.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/783693\/Lyfebulb.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lyfebulb-and-csl-behring-launch-transplantlyfe-a-first-of-its-kind-community-engagement-platform-for-transplant-patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Lyfebulb and CSL Behring Launch TransplantLyfe, a First-of-its-Kind Community Engagement Platform for Transplant Patients"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/420245","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=420245"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/420245\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=420245"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=420245"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=420245"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}